8-K: Canopy Growth Reports Strong Growth in Storz & Bickel and Medical Cannabis, Improves Balance Sheet

Canopy Growth's Q2 FY2025 results show significant growth in key areas like Storz & Bickel and medical cannabis, alongside a strengthened balance sheet.

Summary

• Canopy Growth Corporation announced its financial results for the second quarter of fiscal year 2025, ending September 30, 2024.
• Net revenue was $63 million, a 9% decrease compared to the same quarter last year, but increased by 3% when excluding divested businesses.
• The company's gross margin improved by 100 basis points to 35%, driven by cost savings and a shift to higher-margin medical cannabis sales.
• The adjusted EBITDA loss was $6 million, a 54% improvement year-over-year, due to cost savings.
• Free cash flow was an outflow of $56 million, a 16% improvement year-over-year, mainly due to reduced cash interest expenses.
• Cash and short-term investments increased to $231 million from $195 million at the end of the previous quarter.
• Storz & Bickel net revenue increased by 32% year-over-year, while medical cannabis net revenue grew by 16% in Canada and 12% in international markets.
• The company prepaid US$100 million of its senior secured term loan, further improving its balance sheet.
• Canopy USA completed the acquisition of Wana Brands and is on track to close the acquisition of Acreage Holdings in the first half of calendar year 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong growth in some areas and continued losses in others. The improvements in adjusted EBITDA and free cash flow are positive, but the overall net loss and challenges in the Canadian adult-use market temper the optimism. The strategic moves in the US market are promising for the future.

Positives

• Storz & Bickel experienced strong revenue growth, driven by regulatory changes in Germany and improved US sales.
• Medical cannabis sales showed significant growth in both Canada and international markets.
• The company's cost savings program is yielding positive results, contributing to improved gross margins and reduced operating expenses.
• The balance sheet has been strengthened through debt reduction and increased cash reserves.
• Canopy USA's strategic acquisitions are progressing as planned, positioning the company for growth in the US market.
• The company is seeing positive results from investments in its Tweed and 7ACRES brands, with new strains performing well.

Negatives

• Overall net revenue decreased by 9% compared to the same quarter last year, although this is partially due to divestitures.
• Canada adult-use cannabis sales declined by 24%, partly due to a supply interruption of Wana edibles.
• The company reported a net loss from continuing operations of $131.6 million.
• Operating loss from continuing operations was $46 million, compared to a loss of $7 million in the same quarter last year, with last year's results benefitting from the sale of a facility.
• Free cash flow remains negative, with an outflow of $56 million.

Risks

• The company faces challenges in the Canadian adult-use cannabis market, with declining sales and supply issues.
• The company continues to operate at a loss, despite improvements in adjusted EBITDA.
• The cannabis industry is subject to regulatory changes and uncertainties, which could impact the company's operations and growth.
• The company's future performance is dependent on the successful integration of acquisitions and the execution of its growth strategy.
• The company's ability to achieve positive adjusted EBITDA is dependent on continued cost discipline and improvement in top-line growth.

Future Outlook

The company expects to accelerate momentum in the second half of the fiscal year, with continued growth in key segments and further cost discipline. They anticipate achieving positive Adjusted EBITDA at the consolidated level in the coming quarters. Canopy USA is expected to capitalize on the opportunity for growth in the United States cannabis sector.

Management Comments

• David Klein, Chief Executive Officer, stated that they delivered a solid second quarter led by strong growth across Storz & Bickel, Canadian medical, and European cannabis businesses and are well positioned to accelerate momentum in the second half of the fiscal year.
• David Klein also mentioned that they remain highly optimistic about the momentum building within Canopy USA.
• Judy Hong, Chief Financial Officer, noted that they have demonstrated another quarter of progress towards profitability driven by improvement in gross margins as well as a reduction in SG&A expenses.
• Judy Hong also stated that with expected improvement in top-line growth in the second half of the fiscal year and continued cost discipline, they believe they remain on a path to achieve positive Adjusted EBITDA at the consolidated level in the coming quarters.

Industry Context

The results reflect the ongoing challenges and opportunities in the cannabis industry, with strong growth in specific segments like medical cannabis and vaporizers, while facing headwinds in the adult-use market. The strategic focus on the US market through Canopy USA is a key trend in the industry, as companies seek to capitalize on potential federal legalization.

Comparison to Industry Standards

• Canopy Growth's 35% gross margin is comparable to other established cannabis companies, but there is a wide range depending on the specific market segment and product mix.
• The 54% improvement in adjusted EBITDA loss is a positive sign, but the company still needs to achieve profitability, which is a common challenge in the cannabis sector.
• The 32% growth in Storz & Bickel revenue is strong compared to other vaporizer companies, indicating a successful product and market strategy.
• The 16% growth in Canadian medical cannabis revenue is a positive sign, as many companies are seeing growth in this segment.
• The 24% decline in Canadian adult-use cannabis revenue is a concern, as other companies are seeing more stable or growing sales in this segment. This may be due to the supply interruption of Wana edibles.

Stakeholder Impact

• Shareholders may be encouraged by the improvements in adjusted EBITDA and free cash flow, but concerned about the continued net losses.
• Employees may be impacted by the ongoing cost-saving measures and restructuring efforts.
• Customers will benefit from the re-introduction of Wana edibles and the launch of new products.
• Suppliers may see increased demand as the company expands its operations and product offerings.
• Creditors may be reassured by the company's improved balance sheet and debt reduction.

Next Steps

• The company plans to re-introduce Wana edibles to drive growth in the edibles category.
• They will continue to elevate the quality and variety of their Tweed and 7ACRES flower and pre-roll joint product offerings.
• The company expects to launch an innovative infused pre-roll joint product in both adult-use and medical channels.
• They will continue to expand distribution and improve velocity of their core brands.
• The company expects to increase the supply of cannabis flower to fuel growth in EU medical cannabis markets.
• They will continue to drive growth in the German and broader European market through active marketing campaigns.
• The company will pursue additional distribution gains in the U.S. for Storz & Bickel.
• Canopy USA will continue to integrate Wana Brands and progress with the acquisition of Acreage Holdings.
• Lemurian, Inc. (Jetty) is expected to launch new solventless All-In-One vapes in California and Colorado over the coming weeks, and New York early in calendar year 2025.

Key Dates

Keywords

cannabis, Canopy Growth, Storz & Bickel, medical cannabis, financial results, Q2 FY2025, adjusted EBITDA, gross margin, Canopy USA, Wana Brands, Acreage Holdings